



February 20, 2026

Senator Joy A. San Buenaventura
Chair
Health and Human Services Committee
Hawaii State Senate
Honolulu, Hawaii

Re: Letter of Support for Senate Bill 2933

Dear Madam Chair:

We are writing today to express our strong support for legislation SB 2933, and we understand the Senate Health and Human Services Committee will soon have a hearing on this bill. We appreciate your work to move this important piece of legislation that will take on the high cost of prescription drugs and bring needed relief to patients and families.

Our organization, Americans for Lower Drug Prices (ALDP), is a bipartisan 501(c)(4) advocacy organization founded with one mission: to reduce what Americans pay for prescription drugs.

ALDP gives patients a voice in a debate that's usually dominated by corporate interests. We come from different political backgrounds – Michael, a Republican, served in senior roles in all three of President Trump's campaigns, and Jason, a Democrat, served in key federal roles at HHS, FDA, and NIH. But we've found common ground on this issue because patients in both parties are the ones paying the price.

It is for these reasons that ALDP enthusiastically endorses Senate Bill 2933, sponsored by Senator Angus McKelvey. This legislation would create a Prescription Drug Affordability Board within the Department of Health to perform affordability reviews on high-cost prescription drugs and establish upper payment limits for certain drugs. It also establishes out-of-pocket maximum for prescribed insulin, asthma inhalers, and epinephrine auto-injectors.

SB 2933 takes direct aim at the root cause of unaffordability: manufacturers who have leveraged patent strategies to keep prices far higher than any clinical or market rationale justifies. The creation of a PDAB restores accountability to pharmaceutical pricing and represents a meaningful path forward for patients in Hawaii struggling with high cost of prescription drugs.

We urge the Senate Health and Human Services Committee to support this legislation. Many of the patients and small businesses in Hawaii cannot wait. We are happy to answer any questions or submit written testimony at the Committee's request. We are also happy

to be a resource for the committee and can help bring perspectives on how PDABs are working in other states, patient stories, communications support, or informative data and facts for when the pharmaceutical industry works to stop this vital affordability measure.

Respectfully submitted,

Michael Glassner

Co-Founder, Americans for Lower Drug Prices

Jason Young

Co-Founder, Americans for Lower Drug Prices

PS: Please see our website (<https://lowerrxprices.org>) to learn more about our work.